Clinical Trial Update: Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the safety and efficacy of Symbicort Turbuhaler (budesonide/formoterol) in Japanese patients with asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Symbicort Turbuhaler (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: COMPLETED